Exendin‐4‐based imaging in insulinoma localization: Systematic review and meta‐analysis
- 1 January 2021
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 95 (2) , 354-364
Abstract
Background and context: Glucagon‑like peptide‑1 receptor (GLP‐1 R) based imaging has shown higher sensitivity for insulinoma localization as compared to other anatomic/functional imaging.Methodology: We reviewed the published English literature for GLP‐1 R targeted imaging in insulinoma in PubMed until August 2020 in accordance with PRISMA guidelines using the MeSH terms “((Exendin‐4 PET/CT) OR (Exendin‐4 SPECT/CT) OR (GLP‐1 R imaging)) AND (Insulinoma)”. An individual patient data‐metanalysis (IPD‐MA) was performed, and performance parameters were calculated for the histopathological diagnosis of insulinoma.Main outcome measures: True‐positive (TP), false‐positive (FP), false‐negative (FN), true‐negative (TN), sensitivity (Sn), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) for insulinoma localization.Results: A total of 179 cases (316 lesions) from 16 publications were included for IPD‐MA. For insulinoma localization, exendin‐4‐PET/CT (Sn & PPV: 94%) performed better than exendin‐4‐SPECT/CT (Sn: 63%, PPV: 94%). The Sn was lower in malignant insulinoma cases whereas the Sp was higher in cases with MEN‐1 syndrome. With exendin‐4‐based imaging, FP uptakes in Brunner’s gland, normal pancreas, and other β‐cell pathologies and FN results in pancreatic tail lesions and malignancy were seen in a few patients. TN results suggested the correct diagnosis of other endogenous hyperinsulinemic hypoglycaemia (EHH) subtypes.Conclusion: For insulinoma localization, exendin‐4 PET/CT should be preferred over exendin‐4 SPECT/CT because of higher sensitivity and specificity. FP uptakes in Brunner’s gland, normal pancreas, and other β‐cell pathologies and FN results in tail lesions, and malignant insulinomas are limitations. Higher specificity for insulinoma localization is particularly useful in patients with MEN‐1 syndrome.Keywords
This publication has 35 references indexed in Scilit:
- Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging studyThe Lancet Diabetes & Endocrinology, 2013
- Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant InsulinomasJournal of Nuclear Medicine, 2011
- Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resectionsLangenbeck's Archives of Surgery, 2011
- Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2009
- Glucagon-like Peptide 1–Receptor Scans to Localize Occult InsulinomasNew England Journal of Medicine, 2008
- Strategy for the Surgical Management of Insulinomas: Analysis of 52 CasesDigestive Surgery, 2007
- GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo TargetingJournal of Nuclear Medicine, 2007
- InsulinomaBest Practice & Research Clinical Gastroenterology, 2005
- Peptide Receptors as Molecular Targets for Cancer Diagnosis and TherapyEndocrine Reviews, 2003
- Functioning Insulinoma—Incidence, Recurrence, and Long-Term Survival of Patients: A 60-Year StudyMayo Clinic Proceedings, 1991